Brief: Egetis Therapeutics: Demonstrating Treatment Effects On T3 Levels In MCT8-Deficiency Could Provide Basis For Marketing Approval For Emcitate In US

Egetis Therapeutics AB (publ)

18/01/2022 07:10

Jan 18 (Reuters) - Egetis Therapeutics AB (publ)  EGTX.ST :
    * EGETIS THERAPEUTICS - CONCLUDES THAT DEMONSTRATING
TREATMENT
EFFECTS ON T3 LEVELS IN MCT8-DEFICIENCY COULD PROVIDE BASIS FOR
MARKETING APPROVAL FOR EMCITATE IN US
    * EGETIS THERAPEUTICS AB (PUBL) - NDA IN US IS TARGETED TO
BE
SUBMITTED IN MID-2023 UNDER FAST TRACK DESIGNATION

Source text for Eikon:  ID:nMFN8RkZVP 
Further company coverage:  EGTX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))